Quigley, Phosphagenics form Phusion Laboratories
DOYLESTOWN, Pa. The Quigley Corp. and Phosphagenics Limited on Tuesday announced the formation of a joint venture, to be called Phusion Labs, to develop nonprescription remedies.
The new products will be powered by Phosphagenics’ proprietary, patented TPM technology, a delivery technology that increases the amount and depth of penetration of active molecules into the skin, the companies stated.
“Phosphagenics’ … technology lends itself perfectly to delivery of OTC drugs, as the inclusion of TPM will increase the absorption and efficacy of many OTC active ingredients,” stated Quigley CEO Ted Karkus. “Our signature product Cold-Eeze has built its reputation and robust distribution network on its uniquely effective delivery system. We see the world-class scientific research team at Phosphagenics as the perfect partner to help us leverage our existing network and consumer product expertise.”
Under the terms of the agreement, Quigley and Phosphagenics each will own 50% of Phusion Labs. Quigley will make a one-time payment to Phosphagenics of $1 million and the issuance to Phosphagenics of 1.4 million shares of Quigley common stock.
Additionally, Quigley has contributed $500,000 of initial capital and committed up to $2 million toward the initial development and marketing costs of new products for Phusion Labs. Quigley will oversee distribution, sales and marketing of the new products.
Study: Selenium may cut men’s risk of diabetes
NEW YORK A recent study published in BioMed Central’s open access journal, Nutrition and Metabolism, has shown that men with a higher concentration of selenium in their bodies are less likely to develop diabetes.
Tasnime Akbaraly, from the University of Montpellier, worked with a team of researchers to follow 1,162 healthy French men and women for nine years, monitoring plasma selenium concentrations and incidence of dysglycemia. Akbaraly said during the study period, 127 new cases of dysglycemia occurred, of which 70 were in men and 57 in women. She pointed out, however, that elderly men with high plasma selenium concentrations were “significantly associated with a lower risk of developing dysglycemia over the following nine years.”
“The reason we observed a protective effect of selenium in men but not in women is not completely clear, but might be attributed to women being healthier at baseline, having better antioxidant status in general and possible differences in how men and women process selenium,” Akbaraly said.
Selenium, a trace mineral that is an essential element in several metabolic pathways and is found in such foods as walnuts and various types of fish.
Alison Sweeney becomes spokeswoman for Zyrtec product
FORT WASHINGTON, Pa. “The Biggest Loser” and “Days of Our Lives” star Alison Sweeney will join McNeil Consumer Healthcare as the face of the new Zyrtec Liquid Gels, the company announced Friday.
Sweeney participated in a race in New York to officially welcome the first day of spring. The “Race Against Your Allergies” took place in New York City’s Madison Square Park.
“I’ve partnered with the makers of Zyrtec Liquid Gels as a fun way to kick off the season and show fellow allergy sufferers and lovers of the outdoors how we can outrun our allergy symptoms this year,” Sweeney said.
“We’re excited to be providing allergy sufferers with the opportunity to participate in a fun activity to welcome the first day of spring, while learning how to manage and relieve the everyday allergy symptoms the season can bring,” said Rohinish Hooda, VP marketing, upper respiratory for McNeil Consumer Healthcare.